Rahul Gupta, Kurt A Wargo. Show Affiliations »
Abstract
Entities: Chemical Disease
Mesh： See more » AdultAnti-Bacterial Agents/administration & dosageAnti-Bacterial Agents/adverse effectsAnti-Bacterial Agents/therapeutic useHumansKnee Injuries/complicationsMaleMethicillin Resistance/drug effectsPlasmapheresisPurpura, Thrombotic Thrombocytopenic/chemically inducedPurpura, Thrombotic Thrombocytopenic/therapyRifampin/administration & dosageRifampin/adverse effectsRifampin/therapeutic useStaphylococcal Infections/complicationsStaphylococcal Infections/drug therapyStaphylococcal Infections/microbiologyStaphylococcus aureus/drug effectsStaphylococcus aureus/isolation & purificationTreatment Outcome
Substances： See more » Anti-Bacterial AgentsRifampin
Year: 2005 PMID： 16144880 DOI： 10.1345/aph.1G219
Source DB: PubMed Journal: Ann Pharmacother ISSN： 1060-0280 Impact factor: 3.154